Preclinical Data Supporting Use of CAR T-Cell Therapy in Multiple Myeloma

Video

Noopur S. Raje, MD, a medical oncologist at Massachusetts General Hospital, discusses chimeric antigen receptor T-cell therapy in patients with multiple myeloma. This therapy has been an exciting advancement in both hematology as well as solid tumors, she notes.

Noopur S. Raje, MD, a medical oncologist at Massachusetts General Hospital, discusses chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma. This therapy has been an exciting advancement in both hematology as well as solid tumors, she notes.

Research has been investigating the use of CAR T cells in combination with bb2121 and a lentiviral vector. This recognizes humanized BCMA, Raje explains. The addition of 4-1BB to this also helps with a slow and consistent expansion of the T cells, which also has less toxicity.

Recent Videos
Related Content